NotíciasBenzingaNovo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To... Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To... Benzinga 2026.09.29 10:35 (GMT+0) Abrir em Benzinga Outras notícias Goldman Sachs prevê crescimento de 1,6% no tráfego aéreo em agosto Zepbound supera Wegovy HD na perda de peso, aponta estudo FDA concede status de via rápida ao medicamento de câncer de pulmão da BeyondSpring Scholastic anuncia aquisição da Cottage Door Press por US$ 71 milhões Plug Power fecha acordo de 280 MW para projeto de eletrólise na Dinamarca 1-800-Flowers venderá PersonalizationMall por US$ 45 milhões
